Sheldon Sloan - 01 Jul 2026 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Reporting relationship: Chief Medical Officer
Issuer ticker: SYRE
Reported as of: 01 Jul 2026
Net transaction value: -$730,896
SEC form: 4
Accepted by SEC: 02 Jul 2026, 21:33:02 UTC
Prior SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Heidy King-Jones, as Attorney-in-Fact

Key filing fact

Sheldon Sloan filed Form 4 for Spyre Therapeutics, Inc. (SYRE) on 02 Jul 2026.

Key facts

This page summarizes Sheldon Sloan's Form 4 filing for Spyre Therapeutics, Inc. (SYRE).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2026, 21:33.

Change

Previous filing in this sequence was filed on 03 Jun 2026.
Current net transaction value: -$730,896.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002038798 Primary reporting owner

Sloan Sheldon

Relationship: Chief Medical Officer
Address: 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM
Signature: /s/ Heidy King-Jones, as Attorney-in-Fact
Signature date: 02 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SYRE transaction

Common Stock

Options Exercise

Transaction value
Shares: +8,334
Change %
Price: $27.46^*
Shares after: 8,334
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1

SYRE transaction

Common Stock

Sale

Transaction value: $568,880
Shares: -6,500
Change %: -78%
Price: $87.52
Shares after: 1,834
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1, F2

SYRE transaction

Common Stock

Sale

Transaction value: $162,016
Shares: -1,834
Change %: -100%
Price: $88.34
Shares after: 0
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SYRE transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -8,334
Change %: -2.7%
Price: $0.000000^*
Shares after: 305,000
Date: 01 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,334
Exercise price: $27.46
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

Footnote F2

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F3

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F4

This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.